HOME > 研究業績詳細

研究業績詳細

小松 則夫(コマツ ノリオ)

研究テーマ 造血器腫瘍の病態解析
研究業績(論文) 1.Yoshimi A, Toya T, Nannya Y, Takaoka K, Kirito K, Ito E, Nakajima H, Hayashi Y, Takahashi T, Moriya-Saito A, Suzuki K, Harada H, Komatsu N, Usuki K, Ichikawa M, Kurokawa M. Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in Japan. Ann Oncol 2016;27(5):887-895.
2.Yokomizo T, Watanabe N, Umemoto T, Matsuo J, Harai R, Kihara Y, Nakamura E, Tada N, Sato T, Takaku T, Shimono A, Takizawa H, Nakagata N, Mori S, Kurokawa M, Tenen D G, Osato M, Suda T, Komatsu N. Hlf marks the developmental pathway for hematopoietic stem cells but not for erythro-myeloid progenitors. J Exp Med 2019;216(7):1599-1614.
3.Yasuda H, Tsutsui M, Ota Y, Misawa K, Gotoh A, Hamano Y, Komatsu N. Blastic Plasmacytoid Dendritic Cell Neoplasm Accompanied by Autoimmune Hemolytic Anemia Achieving Complete Remission With Hydroxyurea and Steroids. Geriatr Gerontol Int 2016;16(3):396-398.
4.Yasuda H, Tsutsui M, Ando J, Inano T, Noguchi M, Yahata Y, Tanaka M, Tsukune Y, Masuda A, Shirane S, Misawa K, Gotoh A, Sato E, Aritaka N, Sekiguchi Y, Sugimoto K, Komatsu N. Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. Int J Hematol 2019;110(5):543-549.
5.Yasuda H, Fujiwara N, Ishizaki Y, Komatsu N. Anemia Attributed to Vitamin B6 Deficiency in Post-Pancreaticoduodenectomy Patients. Pancreatology 2015;15(1): 81-83.
6.Watanabe N, Yasuda H, Aota Y, Ando J, Aoyama T, Tanaka M, Gotoh A, Komatsu N. Reactivation of Hepatitis B Virus During Treatment With Hydroxyurea in an Elderly Patient With Essential Thrombocythemia. Geriatr Gerontol Int 2015;15(6):812-813.
7.Watanabe N, Takaku T, Takeda K, Shirane S, Toyota T, Koike M, Noguchi M, Hirano T, Fujiwara H, Komatsu N. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients. Int J Hematol 2018;108(6):588-597.
8.Watanabe N, Kitahara H, Iwao N, Ohta Y, Koike M, Komatsu N. Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment. Geriatr Gerontol Int 2018;18(6):977-979.
9.Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason P.J, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, Takeishi Y. Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Adv 2017;1(15): 1001-1015.
10.Tsukune Y, Sasaki M, Odajima T, Sunami K, Takei T, Moriuchi Y, Iino M, Isoda A, Nakaya A, Muta T, Miyake T, Miyazaki K, Shimizu T, Nakajima K, Igarashi A, Nagafuji K, Kurihara T, Aoyama T, Sugimori H, Komatsu N. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan. Blood Cancer J 2017;7(12):631.
11.Tsukune Y, Sasaki M, Odajima T, Isoda A, Matsumoto M, Koike M, Tamura H, Moriya K, Ito S, Asahi M, Imai Y, Tanaka J, Handa H, Koiso H, Tanosaki S, Hua J, Hagihara M, Yahata Y, Suzuki S, Watanabe S, Sugimori H, Komatsu N. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era. Ann Hematol 2016;95(9):1465-1472.
12.Tsukune Y, Sasaki M, Komatsu N. Reactivation of hepatitis B virus in patients with multiple myeloma. Cancers (Basel) 2019;11(11):E1819. Review
13.Tsukune Y, Komatsu N. Management of Adult Chronic Immune Thrombocytopenia in Japan: Patient and Hematologist Perspectives from a Multi-center Cross-sectional Questionnaire Survey. Intern Med 2016;55(17):2379-2385.
14.Tsukune Y, Isobe Y, Yasuda H, Shimizu S, Katsuoka Y, Hosone M, Oshimi K, Komatsu N, Sugimoto K. Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study. Eur J Haematol 2010;84(4):310-315.
15.Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, Hirano T, Komatsu N, Sugimoto K. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma 2010;51(12):2230-2239.
16.Tomomatsu J, Hamano Y, Ando J, Komatsu N, Sugimoto K. Non-myeloablative allogenic BMT for myelodysplastic syndrome successfully controlled accompanying relapsing polychondritis. Bone Marrow Transplant 2012;47(5):742-743.
17.Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T. Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase. Med Oncol 2018;35(3):38.
18.Takei H, Morishita S, Araki M, Edahiro Y, Sunami Y, Hironaka Y, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Komatsu N. Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One 2014;9(8):e104958.
19.Takei H, Edahiro Y, Mano S, Masubuchi N, Mizukami Y, Imai M, Morishita S, Misawa K, Ochiai T, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations. Br J Haematol 2018;181(6):791-802.
20.Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, Noguchi M, Koike M, Sakamoto J, Oba K, Komatsu N. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. Oncology 2018;94(2):85-91.
21.Tabe Y, Kawase Y, Miyake K, Satoh N, Aritaka N, Isobe Y, Oshimi K, Komatsu N, Miida T, Ohsaka A. Identification of Bcl-2/IgH fusion sequences using real-time PCR and chip-based microcapillary electrophoresis. Clin Chem Lab Med 2011;49(5): 809-815.
22.Suzuki HI, Matsuyama H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K. Computational dissection of distinct microRNA activity signatures associated with peripheral T cell lymphoma subtypes. Leukemia 2013;2710):2107-2111.
23.Suto H, Yasuda H, Isobe Y, Sasaki M, Imai H, Tsutsui M, Oshimi K, Komatsu N, Sugimoto K. Suppression of eIF4E expression by L-Asparaginase. Acta Haematol 2010;123(4):215-219.
24.Sunami Y, Araki M, Kan S, Ito A, Hironaka Y, Imai M, Morishita S, Ohsaka A, Komatsu N. Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. J Bio Chem 2017;292(7):2815-2829.
25.Sunami Y, Araki M, Hironaka Y, Morishita S, Kobayashi M, Liew E.L, Edahiro Y, Tsutsui M, Ohsaka A, Komatsu N. Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. PLoS One 2013;8(2):e57633.
26.Sugiyama M, Ueno Y, Kamo H, Edahiro Y, Miyamoto N, Yamashiro K, Tanaka R, Shimo Y, Komatsu N, Hattori N. Specific Mechanisms of Subarachnoid Hemorrhage Accompanied by Ischemic Stroke in Essential Thrombocythemia: Two Case Reports and a Literature Review. J Neurol 2019;266(8):1869-1878.
27.Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, Isobe Y, Sasaki M, Taka H, Miyazono K, Komatsu N. A Clinically Attainable Dose of L-asparaginase Targets Glutamine Addiction in Lymphoid Cell Lines. Cancer Sci 2015;106(11):1534-1543.
28.Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, Choi M, Sunami Y, Hironaka Y, Noguchi M, Koike M, Noda N, Ohsaka A, Komatsu N. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica 2015;100(2):e46-48.
29.Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, Noguchi M, Koike M, Sato E, Ohsaka A, Komatsu N. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol 2015;101(2):148-153.
30.Shingai N, Harada Y, Iizuka H, Ogata Y, Doki N, Ohashi K, Hagihara M, Komatsu N, Harada H. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes. Int J Hematol 2018;108(6):598-606.
31.Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto K.J, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma 2018;59(5):1105-1112.
32.Sakurai H, Harada Y, Ogata Y, Kagiyama Y, Shingai N, Doki N, Ohashi K, Kitamura T, Komatsu N, Harada H. Overexpression of RUNX1 short isoform has an important role in the development of myelodysplastic/myeloproliferative neoplasms. Blood Adv 2017;1(18):1382-1386.
33.Sakoe Y, Sakoe K, Kirito K, Ozawa K, Komatsu N. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. Blood 2010;115(18):3787-3795.
34.Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K. Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis. Curr Med Res Opin 2018;34(3):531-537.
35.Ohsaka A, Hirota-Komatsu S, Araki M, Komatsu N. Platelet-derived growth factor receptors form complexes with neuropilin-1 during megakaryocytic differentiation of thrombopoietin-dependent UT-7/TPO cells. Biochem Biophys Res Commun 2015;459(3):443-449.
36.Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort. Eur J Haematol 2018;100(6):544-549.
37.Nozaki Y, Mitsumori T, Yamamoto T, Kawashima I, Shobu Y, Hamanaka S, Nakajima K, Komatsu N, Kirito K. Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels. Exp Hematol 2013;41(8):687-696.
38.Nitta H, Gotoh A, Tanaka M, Sekiguchi Y, Ota Y, Noguchi M, Komatsu N. Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement. Br J Haematol 2019;185(1): 183-187.
39.Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K.J, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol 2018;35(7):99.
40.Nakamura R, Ueno Y, Ando J, Matsuda H, Masuda A, Iiduka K, Shingai N, Takanashi M, Yokoyama K, Komatsu N, Hattori N. Clinical and Radiological CLIPPERS Features After Complete Remission of Peripheral T-cell Lymphoma, Not Otherwise Specified. J Neurol Sci 2016;364:6-8.
41.Nakamura A, Misawa S, Chonan M, Kawakami T, Horii T, Komatsu N, Ohsaka A. Efficacy of PCR-based open reading frame typing assay for outbreak investigation of metallo-beta-lactamase-producing Pseudomonas aeruginosa in hematology unit. J Infect Chemother 2018;24(12):1020-1023.
42.Morishita S, Takahashi K, Araki M, Hironaka Y, Sunami Y, Edahiro Y, Tsutsui M, Ohsaka A, Tsuneda S, Komatsu N. Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation. PLoS One 2015;10(3):e0122003.
43.Morishita S, Komatsu N, Kirito K, Koda AH, Sekiguchi Y, Tsuneda S, Noda N. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leuk Res 2011;35(12):1632-1636.
44.Mohammad S, Gotoh A, Morishita S, Komatsu N. Imatinib-sensitive Myeloid Neoplasm With Low Allele Burden of FIP1L1-PDGFRA Fusion Gene in an Elderly Patient. Geriatr Gerontol Int 2016;16(12):1346-1348.
45.Mitsumori T, Nozaki Y, Kawashima I, Yamamoto T, Shobu Y, Nakajima K, Morishita S, Komatsu N, Kirito K. Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells. Exp Hematol 2014;42(9): 783-792.e781.
46.Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. Int J Hematol 2018;107(6):673-680.
47.Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N. The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria. Am J Hematol 2017;92(7):E128-E130.
48.Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N, Mano H, Sugimoto K, Miyazono K. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011;118(26):6881-6892.
49.Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, Jin H, Arase H, Sugimoto K, Nakauchi Y, Masutani H, Maeda M, Yagita H, Komatsu N, Hino O. Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation. PLoS One 2016;11(3):e0150496.
50.Masuda A, Isobe Y, Sugimoto K, Yoshimori M, Arai A, Komatsu N. Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma. Cancer Sci 2020;111(3):807-816.
51.Masubuchi N, Araki M, Yang Y, Hayashi E, Imai M, Edahiro Y, Hironaka Y, Mizukami Y, Kihara Y, Takei H, Nudejima M, Koike M, Ohsaka A, Komatsu N. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia 2020;34(2):499-509.
52.Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F. Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood 2019;134(10):814-825.
53.Liew E.L, Araki M, Hironaka Y, Mori S, Tan T.Z, Morishita S, Edahiro Y, Ohsaka A, Komatsu N. Identification of AIM2 as a downstream target of JAK2V617F. Exp Hematol Oncol 2016;5:2.
54.Kummalue T, Inoue T, Miura Y, Narusawa M, Inoue H, Komatsu N, Wanachiwanawin W, Sugiyama D, Tani K. Ribosomal protein L11- and retinol dehydrogenase 11-induced erythroid proliferation without erythropoietin in UT-7/Epo erythroleukemic cells. Exp Hematol 2015;43(5):414-423.
55.Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis. Int J Hematol 2017;105(3):309-317.
56.Komatsu N, Jun G, Yonezu T, Ohashi Y. Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J Hematol, in press
57.Kobayashi Y, Saita Y, Nishio H, Ikeda H, Takazawa Y, Nagao M, Takaku T, Komatsu N, Kaneko K. Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci 2016;21(5):683-689.
58.Kobayashi T, Nannya Y, Ichikawa M, Oritani K, Kanakura Y, Tomita A, Kiyoi H, Kobune M, Kato J, Kawabata H, Shindo M, Torimoto Y, Yonemura Y, Hanaoka N, Nakakuma H, Hasegawa D, Manabe A, Fujishima N, Fujii N, Tanimoto M, Morita Y, Matsuda A, Fujieda A, Katayama N, Ohashi H, Nagai H, Terada Y, Hino M, Sato K, Obara N, Chiba S, Usuki K, Ohta M, Imataki O, Uemura M, Takaku T, Komatsu N, Kitanaka A, Shimoda K, Watanabe K, Tohyama K, Takaori-Kondo A, Harigae H, Arai S, Miyazaki Y, Ozawa K, Kurokawa M. A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). Am J Hematol 2017;92(12):1324-1332.
59.Kitahara H, Maruyama D, Maeshima A.M, Makita S, Miyamoto K.I, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Tajima K, Terauchi T, Kurihara H, Taniguchi H, Komatsu N, Tobinai K. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. Ann Hematol 2017;96(3):411-420.
60. Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N. Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis. Int J Hematol 2018;107(1):92-97.
61.Kimura K, Tabe Y, Ai T, Takehara I, Fukuda H, Takahashi H, Naito T, Komatsu N, Uchihashi K, Ohsaka A. A novel automated image analysis system using deep convolutional neural networks can assist to differentiate MDS and AA. Sci Rep 2019;9(1):13385.
62.Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers H.F. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother 2017;61(11):e00452-17.
63.Kanemitsu N, Isobe Y, Masuda A, Momose S, Higashi M, Tamaru J, Sugimoto K, Komatsu N. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL. Clin Cancer Res 2012; 18(8):2164-2172.
64.Isobe Y, Tomomatsu J, Tsukune Y, Tsukada N, Sasaki M, Sugimoto K, Komatsu N. Diagnostic problems among chronic lymphocytic leukemia and other indolent B-cell leukemias in a Japanese population. Intern Med 2012;51(15):1977-1981.
65.Isobe Y, Hamano Y, Ito Y, Kimura H, Tsukada N, Sugimoto K, Komatsu N. A Monoclonal Expansion of Epstein-Barr Virus-Infected Natural Killer Cells After Allogeneic Peripheral Blood Stem Cell Transplantation. J Clin Virol. 2013;56(2):150-152.
66.Isobe Y, Aritaka N, Setoguchi Y, Ito Y, Kimura H, Hamano Y, Sugimoto K, Komatsu N. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol 2012;65(3):278-282.
67.Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto K -J, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Potential role for second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis. Oncol Rep 2019;42(6):2836-2843.
68.Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. Mol Cancer Res 2020;18(4):632-643.
69.Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget 2018;9(78):34784-34793.
70.Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto K.J, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group. Leuk Res 2017;54:55-58.
71.Iriyama N, Tokuhira M, Sato E, Sugimoto K-J, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis. Hematol Oncol 2019;37(3):323-325.
72.Iriyama N, Sugimoto K, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T. Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis. Med Oncol 2018;35(11):142.
73.Inoue T, Sugiyama D, Kurita R, Oikawa T, Kulkeaw K, Kawano H, Miura Y, Okada M, Suehiro Y, Takahashi A, Marumoto T, Inoue H, Komatsu N, Tani K. APOA-1 is a novel marker of erythroid cell maturation from hematopoietic stem cells in mice and humans. Stem Cell Rev Rep 2011;7(1):43-52.
74.Inokuchi K, Nakayama K, Tauchi T, Takaku T, Yokose N, Yamaguchi H, Kumagai T, Komatsu N, Ohyashiki K. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations. Leuk Res 2018;65:74-79.
75.Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, Komatsu N. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. Br J Haematol 2019;187(1):e27-e31.
76.Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol 2017;105(6):743-747. Review
77.Ikuta K, Hatayama M, Addo L, Toki Y, Sasaki K, Tatsumi Y, Hattori A, Kato A, Kato K, Hayashi H, Suzuki T, Kobune M, Tsutsui M, Gotoh A, Aota Y, Matsuura M, Hamada Y, Tokuda T, Komatsu N, Kohgo Y. Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol 2017;105(3):353-360.
78.Iizuka K, Yokomizo T, Watanabe N, Tanaka Y, Osato M, Takaku T, Komatsu N. Lack of Phenotypical and Morphological Evidences of Endothelial to Hematopoietic Transition in the Murine Embryonic Head during Hematopoietic Stem Cell Emergence. PLoS One 2016;11(5):e0156427.
79.Ichikawa K, Sugimoto K, Sato E, Sunami Y, Watanabe N, Ushimi T, Komatsu N. 18F-fluorodeoxyglucose positron emission tomography/computed tomography revealed the presence of simultaneous colon cancer in mucosa-associated lymphoid tissue lymphoma. Geriatr Gerontol Int 2011;11(4):537-538.
80.Ichikawa K, Noguchi M, Masuda M, Tsutsui M, Sugimoto KJ, Sekiguchi Y, Imai H, Wakabayashi M, Komatsu N. CD4(+) CD8(-) T cell large granular lymphocytic leukaemia with central nervous system involvement. Histopathology 2012;60(3):519-522.
81.Ichikawa K, Noguchi M, Koike M, Aritaka N, Sekiguchi Y, Sunami Y, Tsutsui M, Hosone M, Hirano T, Gotoh A, Komatsu N. Rituximab plus a CHOP-like regimen, central nervous system prophylaxis, and contralateral testicular irradiation for localized primary testicular diffuse large B-cell lymphoma lead to prolonged progression-free survival. Int J Hematol 2014;100(4):370-378.
82.Ichikawa K, Noguchi M, Imai H, Sekiguchi Y, Wakabayashi M, Sawada T, Komatsu N. A case of T cell prolymphocytic leukemia involving blast transformation. Int J Hematol. 2011;93(5):667-672.
83.Ichikawa K, Edahiro Y, Gotoh A, Iiduka K, Komatsu N, Koike M. Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia. Int J Hematol 2016;104(5):612-620.
84.Honda T, Ando M, Ando J, Ishii M, Sakiyama Y, Ohara K, Toyota T, Ohtaka M, Masuda A, Terao Y, Nakanishi M, Nakauchi H, Komatsu N. Sustainable tumor suppressive effect of iPSC-derived rejuvenated T cells targeting cervical cancers. Mol Ther, in press
85.Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, Tsurumi H, Nakao S, Urabe A, Fujisawa S, Yonemura Y, Kawano F, Oshimi K, Sugimoto K, Matsuda A, Karasawa M, Arai A, Komatsu N, Harigae H, Omine M, Ozawa K, Kurokawa M. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol 2015;169(6):879-886.
86.Hayashi Y, Harada Y, Kagiyama Y, Nishikawa S, Ding Y, Imagawa J, Shingai N, Kato N, Kitaura J, Hokaiwado S, Maemoto Y, Ito A, Matsui H, Kitabayashi I, Iwama A, Komatsu N, Kitamura T, Harada H. NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesis. Blood Adv 2019;3(7):1047-1060.
87.Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Machida S, Nishii K, Honda S, Ohnishi K, Naoe T. Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia. Int J Hematol 2019;109(4):418-425.
88.Harrison C.N, Koschmieder S, Foltz L, Guglielmelli P, Flint T, Koehler M, Mathias J, Komatsu N, Boothroyd R.N, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa R.A. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 2017;96(10):1653-1665.
89.Harada-Shirado K, Ikeda K, Ogawa K, Ohkawara H, Kimura H, Kai T, Noji H, Morishita S, Komatsu N, Takeishi Y. Dysregulation of the MIRLET7/HMGA2 Axis With Methylation of the CDKN2A Promoter in Myeloproliferative Neoplasms. Br J Haematol 2015;168(3):338-349.
90.Gerds A T, Tauchi T, Ritchie E, Deininger M, Jamieson C, Mesa R, Heaney M, Komatsu N, Minami H, Su Y, Shaik N, Zhang X, DiRienzo C, Zeremski M, Chan G, Talpaz M. Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leuk Res 2019;79:38-44.
91.Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N. Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy. Haematologica 2019;104(11):e506-e509.
92.Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto K.J, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database. Ann Hematol 2018;97(11):2081-2088.
93.Edahiro Y, Yasuda H, Ando K, Komatsu N. Self-limiting pregnancy-associated pure red cell aplasia developing in two consecutive pregnancies: case report and literature review. Int J Hematol 2020;111(4):579-584.
94.Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y, Shirane S, Tsutsui M, Noguchi M, Koike M, Imai K, Kirito K, Noda N, Sekiguchi Y, Tsuneda S, Ohsaka A, Araki M, Komatsu N. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol 2014;99(5):625-634.
95.Edahiro Y, Ichikawa K, Suzuki H, Yasuda H, Koike M, Komatsu N. Successful Perioperative Management of Factor XI Deficiency With Administration of Fresh-Frozen Plasma in a Subdural Hematoma Patient. Geriatr Gerontol Int 2016;16(1):143-144.
96.Edahiro Y, Araki M, Komatsu N. Mechanism underlying the development of myeloproliferative neoplasms via mutant calreticulin. Cancer Sci, in press. Review
97.Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol 2019;102(6):516-520.
98.De Marchi F, Araki M, Komatsu N. Molecular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia. Expert Rev Hematol 2019;12(5):285-293. Review
99.Baba T, Tanabe Y, Yoshikawa S, Yamanishi Y, Morishita S, Komatsu N, Karasuyama H, Hirao A, Mukaida N. MIP-1alpha/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice. Blood 2016;127(21):2607-2617.
100.Baba T, Naka K, Morishita S, Komatsu N, Hirao A, Mukaida N. MIP-1α/CCL3-mediated Maintenance of Leukemia-Initiating Cells in the Initiation Process of Chronic Myeloid Leukemia. J Exp Med 2013;210(12):2661-2673.
101.Asakura K, Azechi T, Sasano H, Matsui H, Hanaki H, Miyazaki M, Takata T, Sekine M, Takaku T, Ochiai T, Komatsu N, Shibayama K, Katayama Y, Yahara K. Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. PLoS One 2018;13(3):e0194212.
102.Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, Mizukami Y, Kan S, Shirane S, Edahiro Y, Sunami Y, Ohsaka A, Komatsu N. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood 2016;127(10):1307-1316.
103.Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro Y, Hironaka Y, Osaga S, Ohsaka A, Komatsu N. Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation. Leukemia 2019;33(1):122-131.
104.Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. Int J Hematol 2020;111(2):200-205. Review
105.Araki M, Komatsu N. Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. Cancer Sci 2017;108(10):1907-1912. Review
106.Araki M, Komatsu N. Mutant molecular chaperone activates cytokine receptor as a homomultimer. Oncotarget 2018;9(81):35201-35202. Review
107.Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi H, Komatsu N. Long-term eradication of extranodal Natural killer /T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo. Haematologica 2020;105(3): 796-807.
108.Komatsu N, Jun G, Yonezu T, Ohashi Y. Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J Hematol. 2020 Aug;112(2):176-184.
109.Tanabe Y, Kawamoto S, Takaku T, Morishita S, Hirao A, Komatsu N, Hara E, Mukaida N, Baba T. Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis. Blood Adv. 2020 Dec 22;4(24):6175-6188.
110.Honda T, Ando M, Ando J, Ishii M, Sakiyama Y, Ohara K, Toyota T, Ohtaka M, Masuda A, Terao Y, Nakanishi M, Nakauchi H, Komatsu N. Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers. Mol Ther. 2020 Nov 4;28(11):2394-2405.
111.Morishita S, Ochiai T, Misawa K, Osaga S, Inano T, Fukuda Y, Edahiro Y, Ohsaka A, Araki M, Komatsu N. Clinical impacts of the mutational spectrum in Japanese patients with primarymyelofibrosis. Int J Hematol. 2021;113(4):500-7.
112.Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, Ando J, Tsutsui M, Itakura A, Komatsu N. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. Int J Hematol. 2021;113(1):106-11.
113.Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med. 2020;9(23):8931-9.
114.Morishita S, Yasuda H, Yamawaki S, Kawaji H, Itoh M, Edahiro Y, Imai M, Kogo Y, Tsuneda S, Ohsaka A, Hayashizaki Y, Ito M, Araki M, Komatsu N. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Sci. 2020;112(2):884-92.
115.Masuda A, Isobe Y, Sugimoto K, Yoshimori M, Arai A, Komatsu N. Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma. Cancer Sci. 2020;111(3):807-16.
116.Masubuchi N, Araki M, Yang Y, Hayashi E, Imai M, Edahiro Y, Hironaka Y, Mizukami Y, Kihara Y, Takei H, Nudejima M, Koike M, Ohsaka A, Komatsu N. Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia. 2020;34(2):499-509.
117.Komatsu N, Jun G, Yonezu T, Ohashi Y. Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J Hematol. 2020;112:176-84.
118.Edahiro Y, Yasuda H, Ando K, Komatsu N. Self-limiting pregnancy-associated pure red cell aplasia developing in two consecutive pregnancies: case report and literature review. Int J Hematol. 2020;111(4):579-84.
119.Araki M, Komatsu N. The role of calreticulin mutations in myeloproliferative neoplasms. Int J Hematol. 2020;111(2):200-5.
120.Ando M, Ando J, Yamazaki S, Ishii M, Sakiyama Y, Harada S, Honda T, Yamaguchi T, Nojima M, Ohshima K, Nakauchi H, Komatsu N. Long-term eradication of extranodal Natural killer /T-cell lymphoma, nasal type, by induced pluripotent stem cell-derived Epstein-Barr virus-specific rejuvenated T cells in vivo. Haematologica. 2020;105(3):796-807.
121.Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Morishita S, Komatsu N, Ikeda K, Takeishi Y. Crucial role of hematopoietic JAK2V617F in the development of aortic aneurysms. Haematologica. doi: 10.3324/haematol.2020.264085, online ahead of print.
122.Cervantes F, Ross DM, Radinoff A, Palandri F, Myasnikov A, Vannucchi AM, Zachee P, Gisslinger H, Komatsu N, Foltz L, Mannelli F, Passamonti F, Gilotti G, Sadek I, Tiwari R, Zor E, Al-Ali HK. Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia. doi: 10.1038/s41375-021-01261-x, online ahead of print.
123.Komatsu N, Arita K, Mitsui H, Nemoto T, Hanaki K. Efficacy and safety of ferric citrate hydrate compared with sodium ferrous citrate in Japanese patients with iron deficiency anemia: a randomized, double-blind, phase 3 non-inferiority study. Int J Hematol. doi: 10.1007/s12185-021-03123-9, online ahead of print.
124.Yokokawa T, Misaka T, Kimishima Y, Wada K, Minakawa K, Sugimoto K, Ishida T, Morishita S, Komatsu N, Ikeda K, Takeishi Y. Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms. Haematologica. 2021 Jul 1;106(7):1910-1922.
125.Yasuda H, Yasuda M, Komatsu N. Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. Cancer Sci. 2021 Jul;112(7):2607-2624.
126.Inano T, Araki A, Morishita S, Imai M, Kihara Y, Okuda M, Yang Y, Ito M, Osaga S, Mano M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ando J, Komatsu N. Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia. Sci Rep. 2021 Sep 6;11(1):17702.
127.Ohara K, Kinoshita S, Ando J, Azusawa Y, Ishii M, Harada S, Mitsuishi Y, Asao T, Tajima K, Yamamoto T, Takahashi F, Komatsu N, Takahashi K, Ando M. SCLC-J1, a novel small cell lung cancer cell line. Biochem Biophys Rep.2021 Jul 28;27:101089.
128. Yasuda S, Aoyama S, Yoshimoto R, Li H, Watanabe D, Akiyama H, Yamamoto K, Fujiwara T, Najima Y, Doki N, Sakaida E, Edahiro Y, Imai M, Araki M, Komatsu N, MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. Int J Hematol.2021 Oct;114(4):424-440.
129.Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, Komatsu N, Tanaka N, Tanaka J, Kizaki M, Kawamata T. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. Int J Clin Oncol. 2021 Nov;26(11):2142-2150.
130.Yamauchi T, Yoshida C, Usuki K, Takada S, Matsumura I, Dobashi N, Miyazaki Y, Miyamoto T, Iida H, Asou N, Kuroda J, Ichikawa S, Komatsu N, Mendes W, Honda H, Okubo S, Kurokawa M, Jiang Q, Wei A, Ishizawa K. Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2021 Aug 30;51(9):1372-1382.
131.Ugawa M, Kawamura Y, Toda K, Teranishi K, Morita H, Adachi H, Tamoto R, Nomaru H, Nakagawa K, Sugimoto K, Borisova E, An Y, Konishi Y, Tabata S, Morishita S, Imai M, Takaku T, Araki M, Komatsu N, Hayashi Y, Sato I, Horisaki R, Noji H, Ota S. In silico-labeled ghost cytometry. Elife. 2021 Dec 21;10:e67660.
132.Yasuda H, Morishita S, Mori Y, Tsukune Y, Inano T, Harada S, Komatsu N. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: evidence of a pre-JAK2 clone. Leuk Res. 2021 Jan;100:106496.
133.Ando J, Ueno Y, Yasuda H, Ando M, Edahiro Y, Honda T, Takanashi M, Taniguchi D, Hattori N, Komatsu N. Radiation-Induced Myopathy Developing in a Hodgkin Lymphoma Patient: An Autopsy Case with Systemic Muscle Sampling. Case Rep Oncol. 2021 Mar 8;14(1):338-342.
134.Furukawa Y, Ando M, Azusawa Y, Kinoshita S, Harada S, Ochiai T, Honda T, Sugimoto K, Tabe Y, Komatsu N, Ando J. Persistent immune thrombocytopaenic purpura associated with SARS-CoV-2 infection. EJHaem. 2021 May 4;10:1002/jha2.201.
135.Edahiro Y, Takaku T, Suzuki M, Fukuda Y, Harada S, Kinoshita S, Inano T, Shirane S, Hamano Y, Kondo A, Komatsu N. Intravascular large B-cell lymphoma as a recurrence of primary central nervous system lymphoma after chemotherapy: A case report. Leuk Res Rep. 2021 May 21;15:100249.
136.Harada S, Ando J, Ando M, Nitta H, Inano T, Hirasawa Y, Furukawa Y, Kinoshita S, Kondo A, Ohshima K, Komatsu N. High-grade Primary Central Nervous System Lymphomatoid Granulomatosis: Successful Rituximab Monotherapy. Intern Med. 2021 Dec 1;60(23):3795-3799.
137.Kinoshita S, Ando J, Ando M, Komatsu N. Primary Lymphoma of the Pericardium. Intern Med. 2021 Dec 15;60(24):4005-4006.
138.Furukawa Y, Ando J, Ando M, Kinoshita S, Edahiro Y, Furuta T, Ohshima K, Komatsu N. Long-term spontaneous regression of Stage IV diffuse large B-cell lymphoma. J Clin Exp Hematop. 2021 Sep 10;61(3):168-172.
139.Harada S, Ando J, Ando M, Azusawa Y, Ochiai T, Hashimoto Y, Hirasawa Y, Komatsu N. Sarcoma-like appearance but pathologic Hodgkin lymphoma. Int J Hematol. 2021 Jul;114(1):1-2.
140.Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, Miyake S, Komatsu N. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e810-e816.
141.Kinoshita S, Ando M, Ando J, Ishii M, Furukawa Y, Tomita O, Shirane S, Kishita Y, Yatsuka Y, Eguchi H, Okazaki Y, Komatsu N. Trigenic ADH5 / ALDH2 / ADGRV1 mutations in myelodysplasia with Usher syndrome. Heliyon. 2021 Aug 14;7(8):e07804.

142.Yokomizo T, Ideue T, Morino-Koga S, Tham CY, Sato T, Takeda N, Kubota Y, Kurokawa M, Komatsu N, Ogawa M, Araki K, Osato M, Suda T. Independent origins of fetal liver haematopoietic stem and progenitor cells. Nature. 2022 Sep;609(7928):779-784.
143.Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, Nédélec A, Vertommen D, Roy A, Marty C, Nivarthi H, Defour JP, El-Khoury M, Hug E, Majoros A, Xu E, Zagrijtschuk O, Fertig TE, Marta DS, Gisslinger H, Gisslinger B, Schalling M, Casetti IC, Rumi E, Pietra D, Cavalloni C, Arcaini L, Cazzola M, Komatsu N, Kihara Y, Sunami Y, Edahiro Y, Araki M, Lesyk R, Buxhofer-Ausch V, Heibl S, Pasquier F, Plo I, Vainchenker W, Kralovics R, Constantinescu SN. Secreted Mutant Calreticulins As Rogue Cytokines in Myeloproliferative Neoplasms. Blood. 2022 Nov 10:blood.2022016846.
145.Watari H, Kageyama H, Masubuchi N, Nakajima H, Onodera K, Focia PJ, Oshiro T, Matsui T, Kodera Y, Ogawa T, Yokoyama T, Hirayama M, Hori K, Freymann DM, Imai M, Komatsu N, Araki M, Tanaka Y, Sakai R. A marine sponge-derived lectin reveals hidden pathway for thrombopoietin receptor activation. Nat Commun. 2022 Nov 25;13(1):7262
146.Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Takaku T, Kitamura T. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors. Nat Commun. 2022 Jan 12;13(1):271.
147.Ogama Y, Kumagai Y, Komatsu N, Araki M, Masubuchi N, Akiyoshi H, Matsuura T, Kirisako H, Kyoya A, Nomura F, Ohira Y, Yokokawa T, Yamamoto Y. Phase 1 Clinical Trial of PPMX-T003, a Novel Human Monoclonal Antibody Specific for Transferrin Receptor 1, to Evaluate Its Safety, Pharmacokinetics, and Pharmacodynamics. Clin Pharmacol Drug Dev. 2022 Dec 30.
148.Yasuda H, Hatano T, Honda T, Tsutsui M, Hattori N, Ando M, Komatsu N. Vitamin B6 Deficiency Anemia Attributed to Levodopa/Carbidopa Intestinal Gel Therapy for Parkinson's Disease: A Diagnostic Pitfall for Myelodysplastic Syndrome with Ring Sideroblasts. Intern Med. 2022, in press
149.Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, Edahiro Y, Araki M, Ando M, Komatsu N. Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. J Thromb Thrombolysis. 2022, in press
150.Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A, Takei M, Hatta Y, Nakamura H, Nakayama T, Komatsu N. von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts. Eur J Haematol. 2022 Dec;109(6):779-786.
151.Nishiyama-Fujita Y, Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto K, Fujita H, Fujioka I, Tsuchiya S, Kimura Y, Iwanaga E, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T. Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Ann Med. 2022 Dec;54(1):1244-1254.
152.Yasuda H, Furukawa Y, Nishioka K, Sasaki M, Tsukune Y, Shirane S, Hattori N, Ando M, Komatsu N. Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery with supplementation in two cases. Hematology. 2022 Dec;27(1):463-468
153.Baba T, Hashimoto Y, Yasuda H, Araki M, Edahiro Y, Morishita S, Ochiai T, Shirane S, Ando J, Komatsu N. Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology. 2022 Dec;27(1):157-166
154.Liu C, Imai M, Edahiro Y, Mano S, Takei H, Nudejima M, Kurose A, Morishita S, Ando M, Tsuneda S, Araki M, Komatsu N. Establishment of isogenic induced pluripotent stem cells with or without pathogenic mutation for understanding the pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2022, in press
155.Yasuda H, Komatsu N, Ando J, Ando M. Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):805-811.
156.Edahiro Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Hashimoto Y, Akashi K, Matsumura I, Takenaka K, Komatsu N. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. Int J Hematol. 2022 Nov;116(5):696-711.
157.Morishita S, Hashimoto Y, Furuya C, Edahiro Y, Ochiai T, Shirane S, Inano T, Yasuda H, Ando M, Araki M, Komatsu N. Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia. Eur J Haematol. 2022, in press
158.Yasuda H, Tomizawa Y, Harada S, Sasaki M, Komatsu N, Ando J, Hattori N, Ando M. Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. Heliyon. 2022 Oct 5;8(10):e10928.
159.Mesa R, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Verstovsek S. MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S342.
160.Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K. Correction to: Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022 Oct;116(4):642-643.
161.Komatsu N, Hashimoto Y, Baba T, Otsuka M, Akimoto T, Fernandez J. Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose. Int J Hematol. 2022 Oct;116(4):570-578.
162.Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, Sato T, Qin A, Urbanski R, Shih W, Zagrijtschuk O, Zimmerman C, Mesa RA. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep;18(27):2999-3009.
163.Edahiro Y, Koike M, Nojiri S, Harada Y, Gotoh A, Fujibayashi K, Nishizaki Y, Yanagisawa N, Takaku T, Nitta H, Tsukune Y, Misawa K, Kobayashi H, Komatsu N. A pilot study examining the efficacy of hochuekkito for improving quality of life in patients with myeloproliferative neoplasms. Jpn J Clin Oncol. 2022 Aug 5;52(8):880-886.
164.De Marchi F, Okuda M, Morishita S, Imai M, Baba T, Horino M, Mori Y, Furuya C, Ogata S, Yang Y, Ando J, Ando M, Araki M, Komatsu N. Clinical and biological relevance of CREB3L1 in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res. 2022 May 31;119:106883.
165.Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022 Aug;116(2):215-227.
166.Yasuda H, Ando J, Yoshida S, Ota Y, Komatsu N, Ando M. Diffuse Large B-cell Lymphoma with Adrenal Involvement Presenting as Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorders: Sustained Remission with Methotrexate Termination Alone in Two Cases. Intern Med. 2022 Jul 5.
167.Mori Y, Araki M, Morishita S, Imai M, Edahiro Y, Ito M, Ochiai T, Shirane S, Hashimoto Y, Yasuda H, Ando J, Ando M, Komatsu N. Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients. Cancer Med. 2022 Jul 1.
168.Hasui H, Iseki T, Ueno Y, Kamiyama D, Miyamoto N, Kijima C, Hira K, Komatsu N, Hattori N. Recurrent and Multiple Intracerebral Hemorrhages in Polycythemia Vera Secondary to Myelofibrosis: A Case Report and Literature Review. Case Rep Neurol. 2022 Jun 7;14(2):274-280.
169.Watanabe N, Takaku T, Tsukune Y, Yasuda H, Ochiai T, Yamada K, Nakazawa H, Hotta S, Nishimaki T, Takagi H, Takahashi K, Komatsu N, Ando M. Bosutinib-induced lung injury: a report of two cases and literature review. Int J Hematol. 2022 Jun;115(6):902-905.
170.Uchimura A, Yasuda H, Ando J, Ota Y, Sasaki M, Takaku T, Tsukune Y, Tsutsui M, Edahiro Y, Watanabe N, Ochiai T, Komatsu N, Ando M. Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin. Case Rep Oncol. 2022 Mar 15;15(1):263-266.
171.Harada S, Ando M, Ando J, Ishii M, Yamaguchi T, Yamazaki S, Toyota T, Ohara K, Ohtaka M, Nakanishi M, Shin C, Ota Y, Nakashima K, Ohshima K, Imai C, Nakazawa Y, Nakauchi H, Komatsu N. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. Mol Ther. 2022 Feb 2;30(2):534-549.
172.Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Kada A, Saito AM, Shimoda K, Sugimoto Y, Kurokawa T, Tomita A, Edahiro Y, Akashi K, Matsumura I, Takenaka K, Komatsu N. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. Int J Hematol. 2022 Feb;115(2):208-221.
173.Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022 Jan 11;6(1):238-247.
174.Inano T, Yasuda H, Tsukune Y, Tsutsui M, Wali N, Saeki H, Kajino K, Hino O, Masaki Y, Komatsu N. Abnormal Exacerbation of Moderately Differentiated Gastric Adenocarcinoma in a Patient with TAFRO Syndrome: An Impaired Tumor Immunity? Case Rep Oncol. 2022 Jan 10;15(1):7-11.
175.Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022 Jan 3;52(1):29-38.
176.Watanabe N, Kitahara H, Honda T, Iwasaki H, Iwao N, Komatsu N, Koike M. High incidence of disseminated intravascular coagulation and acute cerebral infarction in acute myeloid leukemia with cup-like nuclei. J Clin Exp Hematop. 2022;62(4):249-252.
177.Edahiro Y, Kurokawa Y, Morishita S, Yamamoto T, Araki M, Komatsu N. Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients. Intern Med. 2022;61(22):3323-3328.




研究者 教育活動